ABSTRACT
In the present study we characterized the cytotoxicity of Wistar rat mononuclear cells from 21 animals which received 10(6) Walker 256 tumor cells by the subcutaneous route. All animals developed the tumor. Cytotoxicity was studied 15 days after inoculation using spleen, thymus and lymph node T lymphocytes as well as macrophages from the peritoneal cavity. A Walker 256 tumor cell suspension and tumor cells in culture (YAC-1) were labelled with 51Cr and used as target cells, according to the Herberman technique and a gamma counter was used for counting. Anti-Walker cell cytotoxicity was significantly decreased in T lymphocytes from the spleen (9.6% vs 51.1% for the control) and thymus (11.5% vs 38.2% for the control), whereas no difference was observed for lymph nodes (41.2% vs 49.5% for the control) or macrophages (43.4% vs 46.3% for the control). Anti-YAC-1 cytotoxicity was significantly decreased in T lymphocytes from all lymphoid organs compared to control: 23.6% vs 42.8% for the spleen, 22.6% vs 41.1% for the thymus, 26.6% vs 42.1% for lymph nodes, and 27.1% vs 46.3% for macrophages. No correlation was observed between tumor weight, and anti-Walker cytotoxicity or anti-YAC-1 cytotoxicity.
Subject(s)
Carcinoma 256, Walker/immunology , Killer Cells, Natural/immunology , T-Lymphocytes/immunology , Animals , Cytotoxicity, Immunologic , Rats , Rats, Wistar , Tumor Cells, CulturedABSTRACT
In the present study we characterized the cytotoxicity of Wistar rat mononuclear cells from 21 animals which received 10(6) Walker 256 tumor cells by the subcutaneous route. All animals developed the tumor. Cytotoxicity was studied 15 days after inoculation using spleen, thymus and lymph node T lymphocytes as well as macrophages from the peritoneal cavity. A Walker 256 tumor cell suspension and tumor cells in culture (YAC-1) were labelled with 51Cr and used as target cells, according to the Herberman technique and a gamma counter was used for counting. Anti-Walker cell cytotoxicity was significantly decreased in T lymphocytes from the spleen (9.6 vs 51.1 for the control) and thymus (11.5 vs 38.2 for the control), whereas no difference was observed for lymph nodes (41.2 vs 49.5 for the control) or macrophages (43.4 vs 46.3 for the control). Anti-YAC-1 cytotoxicity was significantly decreased in T lymphocytes from all lymphoid organs compared to control: 23.6 vs 42.8 for the spleen, 22.6 vs 41.1 for the thymus, 26.6 vs 42.1 for lymph nodes, and 27.1 vs 46.3 for macrophages. No correlation was observed between tumor weight, and anti-Walker cytotoxicity or anti-YAC-1 cytotoxicity.
Subject(s)
Animals , Rats , Carcinoma 256, Walker , Killer Cells, Natural/immunology , T-Lymphocytes , Cytotoxicity, Immunologic , Rats, Wistar , Tumor Cells, CulturedABSTRACT
Rhodium (II) trifluoroacetate (TFARh), rhodium (II) trifluoroacetate adduct with sulfadiazine (TFARh.Sd) and rhodium (II) acetate adduct with sulfisoxazole (RhSx) were tested in mice for acute toxicity, antitumoral activity against Ehrlich ascites carcinoma and for viability of Ehrlich tumor cells in culture. At ip doses up to 60 mumol/kg (40-70 and 59 mg/kg, respectively), these compounds had no toxic effects up to 14 days. At ip doses of 10 mumol kg-1 day-1 for 5 days, TFARh and TFARh.Sd significantly increased the survival rate of mice bearing Ehrlich ascites cells (probability of survival to the end of 34th day, controls = 0.23, TFARh = 0.85, TFARh.Sd = 0.74). No significant effect was observed for RhSx. In vitro, these rhodium complexes at 40 microM significantly increased the number of dead cells in cultured Ehrlich tumor cells.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Carcinoma, Ehrlich Tumor/drug therapy , Rhodium/pharmacology , Acetates/administration & dosage , Animals , Carcinoma, Ehrlich Tumor/mortality , Drug Screening Assays, Antitumor , Mice , Mice, Inbred BALB C , Sulfadiazine/administration & dosage , Sulfisoxazole/administration & dosage , Survival Rate , Time Factors , Trifluoroacetic Acid/administration & dosageABSTRACT
Rhodium (II) trifluoracetate (TFARh), rhodium (II) trifluoracetate adduct with sulfadiazine (TFARh.Sd) and rhodium (II) acetate adduct with sulfisoxazole (RhSx) were tested in mice for acute toxicity, antitumoral activity against Ehrlich ascites carcinoma and for viability of Ehrlich tumor cells in culture. At ip doses up to 60 µmg/kg (40-70 and 59 mg/kg, respectively), these coumpounds had no toxic effects up to 14 days. At ip doses of 10 µmol Kg-1 day-1 for 5 days, TFARh and TFARh.Sd significantly increased the survival rate of mice bearing Ehrlich ascites cells (probability of survival to the end of 34th day, controls = 0.23, TFARh = 0.85, TFARh.Sd = 0.74). No significant effect was observed for RhSx. In vitro, these rhodium complexes at 40 µM significantly increased the number of dead cells in cultured Ehrlich tumor cells